• LAST PRICE
    2.8900
  • TODAY'S CHANGE (%)
    Trending Down-0.1200 (-3.9867%)
  • Bid / Lots
    2.8600/ 16
  • Ask / Lots
    3.1000/ 1
  • Open / Previous Close
    2.9300 / 3.0100
  • Day Range
    Low 2.8700
    High 3.0100
  • 52 Week Range
    Low 2.4600
    High 17.8800
  • Volume
    5,480
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.01
TimeVolumeIOBT
09:32 ET3742.87
09:34 ET6633.01
09:38 ET3503.01
09:39 ET2002.89
09:43 ET1002.97
09:45 ET3002.96
09:48 ET1002.96
09:52 ET1002.89
09:54 ET1002.88
09:57 ET1002.88
09:59 ET1002.88
10:03 ET1002.88
10:06 ET1002.89
10:10 ET1002.87
10:12 ET1002.88
10:14 ET19813
10:15 ET1002.89
10:17 ET1002.89
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIOBT
IO Biotech Inc
72.3M
-1.3x
---
United StatesMIRO
Miromatrix Medical Inc
77.7M
-3.4x
---
United StatesTRVI
Trevi Therapeutics Inc
104.4M
-1.7x
---
United StatesENLV
Enlivex Therapeutics Ltd
80.3M
-3.0x
---
United StatesLUMO
Lumos Pharma Inc
75.9M
-2.6x
---
United StatesTCRR
TCR2 Therapeutics Inc
67.2M
-0.6x
---
As of 2022-10-05

Company Information

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Contact Information

Headquarters
Ole Maaloes Veh 3COPENHAGEN, Denmark 2200
Phone
---
Fax
---

Executives

Chairman of the Board
Peter Hirth
President, Chief Executive Officer, Principal Financial Officer, Director
Mai-Britt Zocca
Chief Accounting Officer
Brian Burkavage
Chief Scientific Officer
Muhammad Al-hajj
Chief Medical Officer
Eva Ehrnrooth

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$72.3M
Revenue (TTM)
$0.00
Shares Outstanding
28.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.17
Book Value
$7.35
P/E Ratio
-1.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.